NanoValent Pharmaceuticals
Directory listingDirectory record status
These labels describe this UNITEMFG record. They do not guarantee current capabilities, certifications, capacity, quality, or fit for a specific job.
- Directory listing
- Listed
- Ownership
- Unclaimed
- Evidence reviewed
- Not recorded
- Last evidence review
- Not recorded
About
NanoValent Pharmaceuticals is a privately-held pharmaceutical company based in Bozeman, Montana, specializing in advanced cancer therapeutics through innovative nanotechnology platforms. The company has developed a proprietary NANO-ADC like TARGETED NANOSPHERE platform that enhances drug delivery, safety, and therapeutic performance for cancer treatments. NanoValent focuses on precision medicine manufacturing, utilizing their flexible nanosphere technology to create targeted drug delivery systems that improve treatment efficacy while reducing adverse effects. Their lead product, NV103, is advancing toward Investigational New Drug status with clinical trials planned for 2026, demonstrating the company's commitment to bringing breakthrough cancer therapies to market. The company operates with strong pharmaceutical manufacturing capabilities and maintains collaborative partnerships with prestigious institutions including Children's Hospital Los Angeles and other leading US academic research centers. This collaborative approach enables NanoValent to leverage cutting-edge research and clinical expertise in their drug development and manufacturing processes. NanoValent's experienced management team brings proven pharmaceutical industry expertise to their operations, positioning the company for continued growth in the competitive healthcare manufacturing sector. Currently seeking Series A financing in 2025, NanoValent represents an emerging leader in targeted cancer therapy development, combining innovative nanotechnology with rigorous pharmaceutical manufacturing standards to address critical unmet medical needs in oncology treatment.